Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892242 · ClinicalTrials.gov registry record · Phase 1
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00892242 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 24 participants.
The verdict
NCT00892242, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.
Interventions
- DRUG Zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892242
The ClinicalTrials.gov registry entry for NCT00892242 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zoledronic acid is the first listed.
NCT00892242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00892242 about?
NCT00892242 is a clinical study titled "Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer". The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.
What is the current status of trial NCT00892242?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00892242?
The interventions under investigation include: Zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00892242?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.